Stock comparison
Haemonetics
Johnson & Johnson
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
HAE
Haemonetics
Market cap
$2.98B
Sector
Healthcare
JNJ
Johnson & Johnson
Market cap
$564.11B
Sector
Healthcare
Overall winner
Johnson & Johnson JNJ
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | HAE | JNJ | Winner |
|---|---|---|---|
| Warren Buffett | 70B | 62C | HAE |
| Benjamin Graham | 85A | 68B | HAE |
| Philip Fisher | 60C | 61C | JNJ |
| Peter Lynch | 54C | 65B | JNJ |
| Joel Greenblatt | 31F | 47D | JNJ |
| Charlie Munger | 54D | 61C | JNJ |
| Terry Smith | 55D | 54C | HAE |
Side-by-side metrics
| Metric | HAE | JNJ |
|---|---|---|
| Market cap | $2.98B | $564.11B |
| P/E (TTM) | 24.8x | 26.7x |
| EV/EBIT | 14.1x | 21.5x |
| ROIC (TTM) | 8.37% | 13.6% |
| Gross margin | 55.74% | 69.12% |
| Net margin | 7.29% | 21.83% |
| Revenue CAGR 5y | 7.65% | 4.58% |
| EPS CAGR 5y | 24.62% | 8.6% |
| Debt / Equity | 1.5x | 0.2x |
| Dividend yield | 0.0% | 2.26% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
HAE leads on
- EPS CAGR 5y24.62%vs 8.6%+65%
- Revenue CAGR 5y7.65%vs 4.58%+40%
- EV/EBIT14.1xvs 21.5x+34%
- P/E (TTM)24.8xvs 26.7x+7%
JNJ leads on
- Dividend yield2.26%vs 0.0%+100%
- Market cap$564.11Bvs $2.98B+99%
- Debt / Equity0.2xvs 1.5x+86%
- Net margin21.83%vs 7.29%+67%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.